A Florida federal judge on Monday barred Actavis from launching its generic version of Shire’s inflammatory bowel disease treatment Lialda until the patent for the drug expires in June 2020, following a second bench trial on the matter.
A lack of definitive rulings from the Federal Circuit on certain issues in Shire's suit over Actavis' proposed generic version of its gastrointestinal drug Lialda emerged as a major point of contention during closing arguments Wednesday in a Florida federal court, in its second bench trial on the matter.
A second bench trial began Monday in Florida in a patent dispute over a generic version of Shire PLC's inflammatory bowel disease treatment Lialda, with the parties offering varying views on the court's task after an appeals court rejected Shire's argument that it applied a review standard incorrectly.
A Florida federal judge on Thursday blocked Actavis Inc.'s bid to launch a generic version of Shire PLC's inflammatory bowel disease treatment Lialda, ruling that Shire's patent for the drug was both valid and infringed.
A Florida federal judge on Thursday declined to rule outright that Irish drugmaker Shire Development LLC's patent for its ulcerative colitis drug Lialda was invalid, rejecting an attempt by Watson Pharmaceuticals Inc. to have the court clear the way for its generic version of the drug.